NCT02367807View on ClinicalTrials.gov

PrEP With TDF/FTC to Prevent HIV-1 Acquisition in Young MSM and Transgender Women of Color

CompletedOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions
HIV
Interventions
DRUG

Emtricitabine and tenofovir disoproxil fumarate

This study will enroll 50 subjects who are offered TDF/FTC for 48 weeks as part of a combined biomedical/behavioral intervention offered in a community-based setting serving high-risk youth in an urban setting.

Trial Locations (1)

19107

Philadelphia FIGHT, Philadelphia

All Listed Sponsors
lead

Philadelphia Fight

OTHER

NCT02367807 - PrEP With TDF/FTC to Prevent HIV-1 Acquisition in Young MSM and Transgender Women of Color | Biotech Hunter | Biotech Hunter